Renal Interventions dedicated a feature article to arteriovenous grafts (AVG) for hemodialysis access, in which Xeltis’ restorative AVG graft aXess is prominently discussed among promising novel devices in vascular access.
According to RI, aXess is a “futuristic implant—a graft built from biosynthetic polymer—which after some months is completely regenerated with live tissue from patients.”
Updates on aXess will feature at the Charing Cross symposium (CX 2022; 26–28 April, London, UK).
View full article on renalinterventions.net
